6-K
Haleon plc (HLN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2026
Commission File Number: 001-41411
Haleon plc
(Translation of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form<br>20-F ☒ | Form<br>40-F ☐ |
|---|
EXHIBIT INDEX
| Exhibit<br>Number | Description |
|---|---|
| 99.1 | 12<br>February 2026 - “Director/PDMR<br>Shareholding” |
99.1
Haleon plc: Director/PDMR Shareholding
12 February 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
On 11 February 2026, the Company received notification of the following transactions as detailed below.
| 1 | Details of the person discharging managerial responsibilities /<br>person closely associated | ||
|---|---|---|---|
| a) | Name | Adrian Morris | |
| 2 | Reason for the notification | ||
| a) | Position/status | General Counsel - PDMR | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction<br>monitor | ||
| a) | Name | Haleon plc | |
| b) | LEI | 549300PSB3WWEODCUP19 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted | ||
| a) | Description of the financial instrument, type of<br>instrument | Ordinary Shares of 0.01 each | |
| Identification code | GB00BMX86B70 | ||
| b) | Nature of the transaction | Acquisition of Partnership Shares and award of Matching Shares<br>under the Company's Share Reward Plan | |
| c) | Price(s) and volume(s) | ||
| Volume(s) | |||
| 31 | |||
| 31 (Matching Shares) | |||
| d) | Aggregated information | ||
| - Aggregated volume | 62 | ||
| - Price | |||
| e) | Date of the transaction | 10 February 2026 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1 | Details of the person discharging managerial responsibilities /<br>person closely associated | ||
|---|---|---|---|
| a) | Name | Jonathan Workman | |
| 2 | Reason for the notification | ||
| a) | Position/status | President, Europe - PDMR | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction<br>monitor | ||
| a) | Name | Haleon plc | |
| b) | LEI | 549300PSB3WWEODCUP19 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted | ||
| a) | Description of the financial instrument, type of<br>instrument | Ordinary Shares of 0.01 each | |
| Identification code | GB00BMX86B70 | ||
| b) | Nature of the transaction | Acquisition of Partnership Shares and award of Matching Shares<br>under the Company's Share Reward Plan | |
| c) | Price(s) and volume(s) | ||
| Volume(s) | |||
| 32 | |||
| 32 (Matching Shares) | |||
| d) | Aggregated information | ||
| - Aggregated volume | 64 | ||
| - Price | |||
| e) | Date of the transaction | 10 February 2026 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HALEON PLC<br><br><br>(Registrant) | |||
|---|---|---|---|
| Date:<br>February 12, 2026 | By: | /s/<br>Amanda Mellor | |
| Name: | Amanda<br>Mellor | ||
| Title: | Company<br>Secretary |